Penumbra, Inc.

    Jurisdiction
    United States
    LEI
    549300RGE06P3ECANU72
    ISIN
    US70975L1070 (PEN)
    Sectors
    1. Healthcare
    2. Medical - Devices

    Scores

    InsiderPie Expert Score
    60 / 100
    Better than peer group:
    53 / 100
    Fair value (Benjamin Graham formula)
    €46.67 374.4% overvalued
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €1.09B
    Gross margin
    66.5%
    EBIT
    €135.89M
    EBIT margin
    12.4%
    Net income
    €125.98M
    Net margin
    11.5%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €1.33B +22.1% €168.32M +33.6%
    €1.51B +13.6% €212.08M +26.0%
    €1.75B +15.7% €261.92M +23.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Elsesser Adam CEO -16K $269.65 -$4.26M
    Grewal Harpreet N/A -186 $272.19 -$50.63K
    Roberts Johanna EVP, Gen. Counsel & Secretary -600 $270.58 -$162.35K
    Elsesser Adam CEO and President -16K $254.53 -$4.05M
    Bose Arani N/A -12K $250.65 -$3.01M

    Congress transactions

    Name Transaction date Value
    Lisa McClain August 13, 2025 $1.00K–$15.00K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    James Anderson 689K $184.24M -41K Sell
    Ray Dalio 1.6K $424.11K -2.4K Sell

    Earnings Calls

    Latest earnings call: July 29, 2025 (Q2 2025)

    Add to watchlist

    Notifications